Brief: Shanghai Henlius Biotech Inc Says NDA For Biosimilar Of Denosumab HLX14 Accepted By NMPA
02/12/2025 13:51
Dec 2 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: NDA FOR BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL- ANTIBODY INJECTION) ACCEPTED BY NMPA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln